

Conquer CF (GI) Innovation Grant 2023

Cystic Fibrosis Australia (CFA) is pleased to announce the Conquer Cystic Fibrosis (GI) Innovation Grant. This grant is looking for 'big thinkers' with great innovative ideas who will make a difference through research to the cystic fibrosis (CF) community. It is open to post-doctoral researchers, scientists, clinicians, medical practitioners, nurses and allied health currently working in the area of CF or proposing to work in CF research in the **gastro-intestinal** (GI) field. GI is defined here to include any part of the GI tract, as well as directly related issues such as nutrition and digestion (including glucose and weight control and the effects of CFTR modulators), and closely associated organs and tissues such as the pancreas, liver and kidney. The researchers will have completed their studies in CF or a related area within the past ten years.

The Conquer CF (GI) Innovation Grant will allow a CF researcher to explore novel concepts at the initial feasibility stage. Innovative applications relating to GI aspects of CF are encouraged, even those lacking pilot data. The grant aims to allow the researcher to generate sufficient data within the one-year grant period to be in a position to apply for additional support from an appropriate funding body to continue the research.

The recipients of the Conquer CF (GI) Innovation Grant are required to provide progress reports on their research to CFA every six months. In addition, and where appropriate, the recipient will be asked to make a presentation at a CFA conference (held every two years) in Australia.

The maximum amount awarded for the Conquer CF (GI) Innovation Grant will be A\$50,000. The actual amount provided will be subject to approval of the applicant's budget.

Applications can be made through the CFA website and must be received no later than **5pm** AEDT **on Friday, 31**st **March 2023**.

Conquer Cystic Fibrosis is a volunteer-run charity founded and driven by West Australian parents of children with the disease. Its primary aim is to fund CF research which will decrease suffering and increase the life span of people with CF.